Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Tharimmune Inc THAR

Healthcare Biotechnology
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:THAR)

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Accesswire November 18, 2024

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Accesswire November 13, 2024

Tharimmune Announces Upcoming Conference Presentations

Accesswire November 4, 2024

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Accesswire October 30, 2024

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Accesswire October 28, 2024

Tharimmune Announces Upcoming Conference Presentations

Accesswire October 25, 2024

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Accesswire September 30, 2024

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Accesswire September 16, 2024

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Accesswire July 22, 2024
View More News ››

Opinion & Analysis (NDAQ:THAR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:THAR)

THAR....Now take a wild guess where it is!!!!!

Yep....... New N.L.O.D Now at $3.68.....U hearing me ????
Iseneschal - October 30, 2024

RE:THAR..... JUst tapped the N.L.O.D at $4.07

You might try re-reading all my posts on this board ! I find it quite hilarious that I get absolutely ZERO likes....I guess I'm just...
Iseneschal - October 30, 2024

THAR.... start the drumroll...just tapped the New

N.L.O.D...........$4
Iseneschal - October 30, 2024

THAR..... JUst tapped the N.L.O.D at $4.07

Declining volume and the sh price trend is not your friend Next support is ........ $3.58 No position since the opening bell ; )
Iseneschal - October 30, 2024

Tharimmune Receives Positive Regulatory Feedback From EMA fo

Just In: $THAR Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary...
whytestocks - October 30, 2024

THAR....in hindsight

I sold too early...mind you it trade sub $5 after I sold. I really don't give a sheet where it goes now....moving on to the next one...
Iseneschal - October 30, 2024
View more Bullboard ››

JZR Gold Inc.

JZR Gold Inc.

JZR Gold Inc. is a Canada-based junior mining resource company. The Company is engaged in the business of the exploration and ...
View More »